Compare Dell Technologies Inc (DELL) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs GSK plc — how do they compare? Dell Technologies Inc trades at $586.28 (market cap $365.31B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: Dell Technologies Inc is far larger — about 4× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and GSK plc for 93 Days on average.
| DELL | GSK | |
|---|---|---|
Market Cap | $365.31B | $91.88B |
Volume | 5,121,365 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $588.67 | $61.18 |
52-Week Low | $111.10 | $43.24 |
Typical Hold Time | 57 Days | 93 Days |
Enterprise Value | $388.20B | $111.88B |
Dividend Yield | 0.44% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies (DELL) trades at $586.28, up 1.26% today, with a bullish technical outlook as the price hovers near resistance at $585. Recent earnings beats, including Q2 2026 EPS of $7.04 versus $4.91 expected, and a raised AI server revenue forecast to $74 billion for fiscal 2027 highlight strong operational momentum. The stock's valuation reflects growth expectations with a P/E of 33.42 and P/S of 2.52.
The outlook remains positive driven by AI server demand, but risks include high valuation sensitivity and competitive pressures. Analyst consensus is bullish with a $566.35 price target, though the current price exceeds this, suggesting near-term consolidation may precede further gains if execution continues.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
